Correction: RON signalling promotes therapeutic resistance in ESR1 mutant breast cancer.

Saved in:
Bibliographic Details
Title: Correction: RON signalling promotes therapeutic resistance in ESR1 mutant breast cancer.
Authors: Dustin D; Lester & Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA.; Program in Translational Biology and Molecular Medicine, Baylor College of Medicine, Houston, TX, USA., Gu G; Lester & Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA.; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA., Beyer AR; Lester & Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA., Herzog SK; Lester & Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA.; Program in Integrative Molecular and Biomedical Sciences, Baylor College of Medicine, Houston, TX, USA., Edwards DG; Lester & Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA., Lin H; Lester & Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA., Gonzalez TL; Lester & Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA., Grimm SL; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA.; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA., Coarfa C; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA.; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA., Chan DW; Lester & Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA., Kim BJ; Lester & Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA., De La O JP; University of Utah Huntsman Cancer Institute, Salt Lake City, Utah, USA., Ellis MJ; Lester & Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA.; Program in Translational Biology and Molecular Medicine, Baylor College of Medicine, Houston, TX, USA.; Department of Medicine, Baylor College of Medicine, Houston, TX, USA., Liu D; Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, TX, USA., Li S; Washington University School of Medicine, St. Louis, MO, USA., Welm AL; University of Utah Huntsman Cancer Institute, Salt Lake City, Utah, USA., Fuqua SAW; Lester & Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA. sfuqua@bcm.edu.; Program in Translational Biology and Molecular Medicine, Baylor College of Medicine, Houston, TX, USA. sfuqua@bcm.edu.; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA. sfuqua@bcm.edu.; Program in Integrative Molecular and Biomedical Sciences, Baylor College of Medicine, Houston, TX, USA. sfuqua@bcm.edu.; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA. sfuqua@bcm.edu.; Department of Medicine, Baylor College of Medicine, Houston, TX, USA. sfuqua@bcm.edu.
Source: British journal of cancer [Br J Cancer] 2025 Oct; Vol. 133 (6), pp. 913-915.
Publication Type: Published Erratum
Journal Info: Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print Cited Medium: Internet ISSN: 1532-1827 (Electronic) Linking ISSN: 00070920 NLM ISO Abbreviation: Br J Cancer Subsets: MEDLINE; In Process
Database: MEDLINE Ultimate
Description
ISSN:1532-1827
DOI:10.1038/s41416-025-03096-0